Atlas Brown Inc. Acquires 6,253 Shares of Organon & Co. (NYSE:OGN)

Atlas Brown Inc. boosted its stake in shares of Organon & Co. (NYSE:OGN) by 21.5% during the 4th quarter, HoldingsChannel reports. The fund owned 35,357 shares of the company’s stock after purchasing an additional 6,253 shares during the period. Atlas Brown Inc.’s holdings in Organon & Co. were worth $528,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in OGN. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Organon & Co. by 3.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 44,144 shares of the company’s stock valued at $659,000 after purchasing an additional 1,284 shares during the last quarter. Range Financial Group LLC bought a new stake in Organon & Co. in the fourth quarter worth $827,000. CWA Asset Management Group LLC increased its position in Organon & Co. by 27.0% during the fourth quarter. CWA Asset Management Group LLC now owns 23,596 shares of the company’s stock valued at $352,000 after acquiring an additional 5,017 shares during the last quarter. Versant Capital Management Inc increased its position in Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after acquiring an additional 1,324 shares during the last quarter. Finally, Garden State Investment Advisory Services LLC purchased a new stake in shares of Organon & Co. in the third quarter valued at $203,000. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Stock Performance

Organon & Co. stock remained flat at $16.00 during mid-day trading on Friday. The company’s stock had a trading volume of 3,097,837 shares, compared to its average volume of 2,953,566. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The company has a 50 day simple moving average of $15.41 and a 200 day simple moving average of $18.44. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company has a market capitalization of $4.12 billion, a PE ratio of 3.17, a PEG ratio of 0.81 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the company posted $0.78 earnings per share. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities research analysts forecast that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.00%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.